Format

Send to

Choose Destination
See comment in PubMed Commons below
Emerg Infect Dis. 2004 Oct;10(10):1812-5.

Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America.

Author information

1
Department of Paediatrics, University of Oxford, Oxford OX3 9DU, UK. andrew.pollard@paediatrics.ox.ac.uk

Abstract

Clusters of meningococcal disease caused by a hyperinvasive lineage of Neisseria meningitidis, the ST11 complex, bearing a serogroup C polysaccharide capsule, have been prominent in Europe and North America since the early 1990s. This situation has led to expensive public health measures for outbreak control and, finally, to the introduction of a serogroup C glyconjugate vaccine into the primary immunization schedule in the United Kingdom and elsewhere. ST11 complex meningococci may also express serogroup W135 polysaccharide capsules. We investigated the level of population immunity to this hyperinvasive clone in association with the appearance of outbreaks of meningococcal disease in southern British Columbia. We found that most adults and almost all children were apparently susceptible to infection with ST11 complex meningococci bearing both C and W135 polysaccharide capsules, which suggests that a vaccine program directed against only serogroup C meningococci may be insufficient to prevent hyperinvasive ST11 disease.

PMID:
15504268
PMCID:
PMC3323278
DOI:
10.3201/eid1010.040335
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for CDC-NCEZID Icon for PubMed Central
    Loading ...
    Support Center